ZURA · Zura Bio Ltd

$5.75 +0.10 (+1.74%) At close · Sep 2

Russell 2000 member Rebalance outlook locked

Market Cap

$542.39M

95.83M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income

-$68.65M -31%

FY2025

Diluted EPS

-$1.06 -76.7%

FY2025

Operating Cash Flow

-$64.82M -130.9%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022
Research & Development	—	—	—	$58.36M	$42.08M	$24.4M	$44M	—
General & Administrative	+143.6%	—	—	$34.39M	$33.16M	$30.79M	$18.64M	$2.29M
Depreciation & Amortization	—	—	—	$49.01K	$49K	$9000	—	—
Total Operating Expenses	—	—	—	$92.75M	$75.25M	$55.19M	$62.64M	—
Operating Income	—	—	—	-$92.75M	-$75.25M	-$55.19M	-$62.64M	-$2.68M
Interest Income	+2131.8%	—	—	$6.04M	$6.34M	$8M	$2.19M	$570
Other Non-Operating Income	+2.0%	—	—	$6.93M	$6.6M	$2.79M	$2.08M	$6.22M
Investment Income (Loss)	—	—	—	—	—	—	—	$2.08M
Pretax Income	—	—	—	-$85.82M	-$68.65M	-$52.4M	-$60.56M	—
Income Tax	—	—	—	—	—	$0	$0	—
Net Income	—	—	—	-$85.74M	-$68.65M	-$52.4M	-$60.36M	-$25.7M
Net Income Available to Common Stockholders	—	—	—	—	-$99.35M	-$45.39M	-$69.24M	—
EPS (Basic) USD/shares	—	—	—	-$1.13	-$1.06	-$0.60	-$2.09	—
EPS (Diluted) USD/shares	—	—	—	-$1.13	-$1.06	-$0.60	-$2.09	—
Shares Outstanding (Basic Avg) shares	—	—	—	—	94.16M	75.07M	33.06M	—
Shares Outstanding (Diluted Avg) shares	—	—	—	—	94.16M	75.07M	33.06M	—

Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 5.35×

EV/EBIT

—

Peer median 10.37×

P/E (TTM)

—

Peer median 13.00×

Peer medians compare against the 304 similar-size Biotechnology companies (of 514 listed).

Key facts CIK 1855644 CUSIP G9TY5A101 13F (30d) 89 filings 89 filers Visit website Investor relations